London, UK and Cambridge, MA, April 16th, 2008 – InforSense Ltd., the leading provider of embedded enterprise intelligence, today announced that it has signed a three year collaboration agreement with Dana-Farber Cancer Institute. The deal includes InforSense’s ClinicalSense cohort selection and clinical decision support product, and its wider translational research capabilities to support improved disease understanding and patient care in oncology.
Principal Investigators and researchers at Dana-Farber are using ClinicalSense to access integrated clinical, sample, and research data via non-technical web pages. ClinicalSense is a web based tool for cohort selection and study design; it enables users to ‘slice and dice’ summary clinical data, compare sample relevant characteristics and select appropriate sample subsets to optimize study design. Once the studies have been completed, experimental data is integrated into the InforSense platform, where it is analyzed using extensive statistical tools to identify biomarkers or develop predictive models. Statisticians and computational biologists pre-build sophisticated workflows to perform this analysis and present it back via further web pages. This provides a self-service portal to researchers that supports direct access to data and analysis workflows, saving them time and ensuring consistent best practice analysis is applied
“At the Dana-Farber Cancer Institute, we need to have access to a wide range of clinical, experimental and patient specimen data that exists in disparate data stores. To drive cancer research and advance cancer care, we need an efficient way to integrate this data and make it available to a diverse group of developers, statisticians, study designers, and biologists,” said John Quackenbush, Professor of Biostatistics and Computational Biology. “We chose ClinicalSense and the InforSense Translational Research Solution because it provides advanced data integration and ETL capabilities, combined with analytical power and process flexibility. Using this solution, analyses can be quickly developed, modified and deployed via a web interface to our scientists.”
“It is a great honor to be working with Dana-Farber and supporting their important oncology research,” said Jonathan Sheldon, Chief Scientific Officer, InforSense. “Our extensive experience in translational research, coupled with the analytical power, process flexibility and integration capabilities of our technology will enable Dana-Farber’s to build a platform to fully leverage their patient data; helping improve our understanding of oncological disorders.”
Read the Dana-Farber Case Study here.
InforSense ClinicalSense™ is a decision support environment that enables clinicians to interact directly with clinical and sample status data. Designed by clinical researchers for clinical researchers, ClinicalSense eliminates the dependence on IT for ad hoc queries and analysis of patient data. Now clinicians can perform any analysis of patient data on the fly with immediate results. This enable them to rapidly generate and test hypotheses to discover key events that influence clinical outcome ClinicalSense is unique in its support for relevant clinical data types and visualization methods for those involved in clinical research.
About InforSense Translational Research Solution
The InforSense Translational Research Solution provides a powerful and flexible framework to integrate and analyze clinical, patient specimen and experimental data for translational research. The solution builds on InforSense’s expertise developing translational research analytics applications for the world’s leading research institutes. It incorporates the power of the InforSense platform with expertise in micro-array analysis from BioSense, cohort identification and clinical decision support from ClinicalSense and automated QC and analysis of Genome Wide Association Studies from GenSense. This enables translational analysis to be quickly implemented out of the box with minimum configuration, but enables best practice analytical workflows to be developed and modified by internal teams, providing the flexibility to manage this evolving research field. Features include:
- Easy integration of data sets - All clinical, patient sample and experimental data can be integrated into a consistent informatics platform improving decision making by incorporating all available data
- Simple web interface - Study designers and scientists can query and analyze the data through simple web interfaces produced by expert developers and statisticians, removing bottlenecks in accessing the data
- Flexible platform - Workflows can be quickly developed and evolved enabling best practices to be flexibly optimized rather than needing to re-implement systems with each iteration
- Advanced and scalable analytics - Proven scalability of the InforSense platform allows large data sets to analyzed using a wide variety of pre-integrated tools such as R and SAS providing a future proof environment.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute (http://www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.
InforSense Ltd., the leader in agile, predictive, and visual embedded enterprise analytics, enables organizations to orchestrate and optimize their business-critical decision-making processes. Leading pharmaceutical and biotechnology, consumer goods, healthcare, financial services, manufacturing and communications companies are using the company’s flagship product, InforSense, to enhance productivity by embedding analytics within their business processes. The company is privately held, with European headquarters in London, UK and North American headquarters in Cambridge, Massachusetts.